Clinical trials
Showing 1 - 8 of 8
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma (NRG-BN011)
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (Chimerix ACTION)
BPM31510IV-11 - A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB)
A phase 2 double-blind, RandomizEd, prospective, placebo controlled STudy of NanO2 TM combined with Radiation and temozolomide in patients with newly-diagnosed glioblastoma multiformE: RESTORE
A phase 2 double-blind, RandomizEd, prospective, placebo controlled STudy of NanO2 TM combined with Radiation and temozolomide in patients with newly-diagnosed glioblastoma multiformE: RESTORE
Alliance A072201, Randomized Phase 2 Trial of Anti-LAG-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma
The purpose of this study is to compare the usual treatment to using the study drugs, Relatlimab and Nivolumab. The use of the study drugs, Relatlimab and Nivolumab, could shrink or stabilize your cancer.
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)
This is a two-arm, randomized, double blind, placebo-controlled study of Optune (Tumor Treating Fields at 200 kHz) to the brain concomitant with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune concomitant with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
A PHASE II, SINGLE-ARM, MULTICENTER, OPEN‑LABEL STUDY OF ZANZALINTINIB IN PARTICIPANTS WITH RECURRENT OR PROGRESSIVE MENINGIOMA
The objective of the study is to evaluate efficacy and safety of Zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Showing 1 - 8 of 8